Acute Kidney Injury Clinical Trial
Official title:
BIcarbonato di Sodio e N-Acetilcisteina Nella Prevenzione Della Nefropatia da Mezzo di Contrasto Nell'infaRto mIocardico acutO(Registro BINARIO)
Contrast-induced nephropathy (CIN) represents a potential complication of diagnostic and therapeutic procedures in interventional cardiology, especially in the acute setting of primary PCI. The investigators will test the efficacy of sodium bicarbonate (NaHCO3) and N-acetylcysteine (NAC) on the prevention of acute events and CIN in patients with acute myocardial infarction.
Introduction Contrast-induced nephropathy (CIN) represents a potential complication of
diagnostic and therapeutic procedures in interventional cardiology. In the setting of
elective procedures, the strategy of sodium bicarbonate (NaHCO3) and N-acetylcysteine (NAC)
infusion has been shown to reduce the incidence of CIN in high-risk patients. The efficacy
of this strategy has not been demonstrated in the case of primary percutaneous coronary
intervention (PCI).
Aim of the study The aim is to assess the efficacy of the strategy of sodium bicarbonate
154mEq/l + glucose solution 5% (infusion rate: 3 mL • kg-1 • h-1 for 1 hour followed by 1 mL
• kg-1 • h-1 for 6 hours) and NAC (1200 mg i.v. followed by 1200 mg bid for the next 48
hours) in reducing the incidence of CIN in patients with STEMI undergoing primary or rescue
PCI. As control group, a population of STEMI patients treated with NAC (1200 mg i.v.
followed by 1200 mg bid for the next 48 hours) + conventional hydration with saline solution
0.9% will be retrospectively enrolled. According to the common definition, CIN will be
defined as increase of the level of serum creatinine >0,5 mg/dL and/or increase ≥25% serum
creatinine and/or decrease ≥25% of the glomerular filtration rate (GFR) as calculated with
the MDRD Modification of Diet in Renal Disease)formula at 48 hours after PCI compared with
baseline value after primary PCI.
Study Design This is a two-center (Policlinico Gemelli and Policlinico Casilino, Rome,
Italy), prospective, spontaneous (not sponsored) observational study.
Patient population
Inclusion criteria:
- Consecutive patients with ST-Segment Elevation Myocardial Infarction (STEMI) as
diagnosed according to the ACC (American College of Cardiology) criteria:
- ischemic symptoms;
- ECG variations: ST-elevation (>0,05 mV) in two or more contiguous leads;
- Increase of the biochemical markers of myocardial necrosis (troponin T, cTNT).
- Indication to urgent coronary angiography and primary or rescue PCI
Exclusion criteria:
- Patients with history of allergic reaction to NAC (Fluimucil, Zambon Group Spa, Milan,
Italy)
- Chronic hemodialysis
- Age > 90 years
Study protocol Patients will be treated with 154 mEq/L of sodium bicarbonate and glucose 5%
solution (infusion rate of 3 mL • kg-1 • h-1 for 1 hour followed by 1 mL • kg-1 • h-1 for 6
hours) plus NAC (1200 mg i.v. followed by 1200 mg bid for the next 48 hours). As control
group, a population of STEMI patients treated with conventional hydration with saline
solution 0,9% and NAC (1200 mg i.v. followed by 1200 mg bid for the next 48 hours) according
to the common clinical practice of the Department of Cardiovascular Medicine of the
Policlinico Agostino Gemelli and of Cardiology Department of the Policlinico Casilino will
be retrospectively enrolled.
Endpoints:
Primary endpoint:
- Composite endpoint (death/need for dialysis/CIN)
Secondary endpoints:
- assessment of individual major adverse events (death, re-infarction, need for dialysis)
during at 1, 6 and 12 months
- assessment of the incidence of CIN defined as increase of the level of serum creatinine
>0,5 mg/dL and/or increase ≥25% serum creatinine and/or decrease ≥25% of the glomerular
filtration rate (GFR) as calculated with the MDRD formula at 48 hours after PCI
compared with baseline value.
;
Observational Model: Case Control
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |